Gen AI opportunities in Pharma

In this episode of EY.ai Unplugged, Suresh Subramanian, Partner and Lifesciences Leader, EY India, discusses how AI is starting to reshape the Indian pharmaceutical sector. Drawing on EY research, he notes that over 65% of CEOs see AI as a key operational lever, with many already taking early steps. From faster drug discovery to smarter clinical trials, AI is no longer a future promise—it’s already in play.

Key takeaways:

    1. AI’s transformative power: Pharma companies are moving beyond exploration—AI is now being piloted across critical functions like R&D, signaling a shift from potential to real-world impact.
    2. Faster drug discovery: AI can reduce drug discovery timelines from months to weeks, accelerating innovation.
    3. Efficiency in trials: One of the biggest benefits of AI is in enhancing efficiency and optimizing costs in development and clinical trials, from patient recruitment to data identification.
    4. AI is here: AI is no longer a future concept — it is already shaping pharma operations today.
    Related topics
    AI
    Life sciences

    In conversation with:

    Suresh Subramanian
    Partner and Lifesciences Leader, EY India

    For your convenience, a full text transcript of this podcast is available on the link below:


    If you would like to listen to our podcasts on the go:

    Podcast

    Episode 20

    Duration

    2m 8s

    How EY can help

    In this series

    EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients.